Results for “vaccines”
Merck And Co
** Merck & Co., Inc. is a global, research‑driven pharmaceutical company headquartered in Kenilworth, New Jersey, known for developing prescription medicines, vaccines, biologic therapies, and animal health products. **CONTENT:** ## Overview Merck & Co. (often styled **Merck & Co.**) is one of the world’s largest **pharmaceutical** and **biotechnology** firms, operating in more than 140 countries and generating annual revenues exceeding $60 billion. The company’s product portfolio spans **prescription drugs** for oncology, infectious diseases, cardiovascular health, and immunology, as well as a leading line of **vaccines** (including the widely used **Gardasil** HPV vaccine) and a robust **animal health** division. Merck’s business model blends deep‑pipeline research, strategic acquisitions, and a global commercial network that delivers medicines to both high‑income and emerging‑market patients. The firm is distinguished by its long‑standing commitment to **R&D intensity**—spending roughly 10 % of revenue on research each year—and by a culture that emphasizes scientific rigor, ethical standards, and corporate responsibility. Merck’s corporate slogan, “**Science Wins**,” reflects its belief that breakthrough science can solve some of the most pressing health challenges of the 21st century. ## History/Background Merck & Co. traces its roots to the **Merck family’s** 1668 pharmacy in Darmstadt, Germany. The American offshoot was founded in **1891** when **George E. Merck**, a German‑born chemist, established the **Merck & Co.** subsidiary in New York to import and market German‑produced chemicals and medicines. The company became an independent American entity after **World I**, when the U.S. government seized German‑owned assets under the Trading with the Enemy Act; Merck & Co. was subsequently reorganized as a U.S. corporation. Key milestones include the 1944 discovery of **penicillin** mass production, the 1955 launch of **Mevacor** (the first statin), and the 1991 introduction of **Vioxx**, a COX‑2 inhibitor that, despite later controversy, underscored Merck’s capacity for blockbuster drug development. In **2009**, Merck completed the acquisition of **Schering‑Plough**, expanding its vaccine and animal health businesses. Most recently, the **2023** acquisition of **Acceleron Pharma** bolstered its pipeline in rare‑disease therapeutics. ## Key Information - **Headquarters:** Kenilworth, New Jersey, USA. - **CEO (as of 2024):** **Robert M. Miller**, who succeeded **Kenneth C. Frazier** in 2023. - **Revenue (2023):** $60.2 billion; **Net Income:** $13.5 billion. - **Employees:** ~ 74,000 worldwide. - **Core Segments:** 1. **Pharmaceuticals** – oncology (Keytruda‑style immunotherapies), infectious disease (Keytruda, Veklury for COVID‑19), cardiovascular, diabetes. 2. **Vaccines** – human (Gardasil, Pneumovax, Shingrix) and animal health vaccines. 3. **Animal Health** – products for livestock, pets, and aquaculture under the **Merial** brand. - **R&D Footprint:** 27 research sites, including the flagship **Merck Research Laboratories** in Rahway, New Jersey, and collaborations with academic institutions and biotech startups. - **Major Achievements:** Development of **Keytruda** (pembrolizumab), a checkpoint inhibitor that has become a cornerstone of modern oncology, and **Veklury** (remdesivir), the first FDA‑approved antiviral for COVID‑19. ## Significance Merck & Co.’s impact extends beyond its financial heft. Its **scientific breakthroughs**—particularly in immuno‑oncology and vaccine technology—have reshaped treatment standards for cancers, viral infections, and chronic diseases, saving millions of lives globally. The company’s **global access programs**, such as the **Merck for Mothers** initiative and tiered pricing for essential medicines, illustrate a commitment to health equity, especially in low‑income regions. Economically, Merck is a bellwether for the **pharmaceutical sector**, influencing market trends, pricing debates, and regulatory policies. Its sizable **R&D investment** drives innovation ecosystems, spawning spin‑offs, patents, and collaborative research networks. Moreover, Merck’s **animal health division** supports food security by improving livestock health, thereby contributing to the broader agricultural economy. The firm’s legacy of navigating **ethical challenges**—from the Vioxx recall to pricing scrutiny—offers case studies in corporate governance, risk management, and the balance between profit and public health. As the industry confronts emerging threats like antimicrobial resistance and the need for next‑generation vaccines, Merck’s scale, scientific depth, and global reach position it as a pivotal player in shaping the future of healthcare. **INFOBOX:** - Name: Merck & Co., Inc. - Type: Publicly traded multinational pharmaceutical and animal health corporation - Date: Founded 1891 (U.S. operations) - Location: Kenilworth, New Jersey, United States - Known For: Development of Keytruda (cancer immunotherapy), Gardasil (HPV vaccine), and Veklury (COVID‑19 antiviral) **TAGS:** pharmaceuticals, biotechnology, vaccines, oncology, animal health, R&D, global health, corporate governance
Economics & BusinessSanofi
**Sanofi** **Sanofi** is a French multinational pharmaceutical and healthcare company headquartered in Paris, France, that develops and markets a wide range of pharmaceuticals, vaccines, and consumer
Economics & BusinessPfizer Inc
**Pfizer Inc** **Pfizer Inc** is a multinational pharmaceutical and biotechnology corporation headquartered in New York City, New York, United States, and is one of the oldest pharmaceutical companie
Economics & BusinessGlaxoSmithKline
GlaxoSmithKline plc is a British multinational pharmaceutical and biotechnology company headquartered in London, known for developing prescription medicines, vaccines, and consumer health products.